Pila Pharma AB (FRA:5KC) Return-on-Tangible-Asset: -267.05% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5KC Pila Pharma AB FRA:5KC
49 GF Score
Price €0.11
GF Value €0.15
! 3 Warning Signs
View Full Analysis

What is Pila Pharma AB Return-on-Tangible-Asset?

Pila Pharma AB FRA:5KC -3.18% 49 Return-on-Tangible-Asset is -267.05% as of Dec. 2025. GuruFocus rates FRA:5KC with a GF Score™ of 49/100 and a GF Value™ of €0.15. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Pila Pharma AB ranks worse than 92.02% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pila Pharma AB's annualized Net Income for the quarter that ended in Dec. 2025 was €-2.35 Mil. Pila Pharma AB's average total tangible assets for the quarter that ended in Dec. 2025 was €0.88 Mil. Therefore, Pila Pharma AB's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -267.05%.

The historical rank and industry rank for Pila Pharma AB's Return-on-Tangible-Asset or its related term are showing as below:

FRA:5KC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -208.18   Med: -153.48   Max: -112.05
Current: -208.18

During the past 8 years, Pila Pharma AB's highest Return-on-Tangible-Asset was -112.05%. The lowest was -208.18%. And the median was -153.48%.

FRA:5KC's Return-on-Tangible-Asset is ranked worse than
92.02% of 1416 companies
in the Biotechnology industry
Industry Median: -35.915 vs FRA:5KC: -208.18

Pila Pharma AB  (FRA:5KC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Pila Pharma AB Return-on-Tangible-Asset Related Terms


Pila Pharma AB Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Pila Pharma AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pila Pharma AB Return-on-Tangible-Asset Chart

Pila Pharma AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial -111.97 -140.08 -141.06 -193.47 -161.28

Pila Pharma AB Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -160.89 -177.23 -354.92 -208.40 -267.05

FRA:5KC vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Pila Pharma AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pila Pharma AB Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pila Pharma AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Pila Pharma AB's Return-on-Tangible-Asset falls into.


FRA:5KC
49GF Score
Pila Pharma AB FRA:5KC
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pila Pharma AB Return-on-Tangible-Asset Calculation

Pila Pharma AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-1.562/( (0.447+1.49)/ 2 )
=-1.562/0.9685
=-161.28 %

Pila Pharma AB's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-2.346/( (0.267+1.49)/ 2 )
=-2.346/0.8785
=-267.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of -267.05% mean?
Pila Pharma AB (FRA:5KC) has a Return-on-Tangible-Asset of -267.05% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pila Pharma AB and its competitors. According to the industry distribution chart, Pila Pharma AB ranks #1303 out of 1416 companies in the Biotechnology industry, placing it in the top 92%.
Is Pila Pharma AB's Return-on-Tangible-Asset too high?
Pila Pharma AB's current Return-on-Tangible-Asset is -267.05%. Based on the distribution chart, Pila Pharma AB ranks #1303 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pila Pharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pila Pharma AB ranks #1303 out of 1416 companies for Return-on-Tangible-Asset. This places Pila Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pila Pharma AB and its competitors. Pila Pharma AB's current Return-on-Tangible-Asset is -267.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Pila Pharma AB (FRA:5KC) has a current Return-on-Tangible-Asset of -267.05%. The stock's GF Value™ is €0.15, compared to a current price of €0.11 — trading 29% below its estimated fair value. The current Return-on-Tangible-Asset is -267.05%. Pila Pharma AB's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Pila Pharma AB (FRA:5KC), the current Return-on-Tangible-Asset is -267.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pila Pharma AB (FRA:5KC) Overvalued in 2026?

Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued. The current stock price of €0.11 is trading 29% below its estimated GF Value™ of €0.15.

Key valuation signals for FRA:5KC:

  • Return-on-Tangible-Asset: -267.05%
  • GF Value™: €0.15 vs. price of €0.11 (29% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the FRA:5KC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pila Pharma AB Business Description

Other Exchanges PILA:Sweden
Address Norra Vallgatan 72, Malmo, SWE, 211 21
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
49GF Score

Get the complete analysis for FRA:5KC

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.15
GF Value